Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

VOR
Vor Biopharma Inc. Common Stock
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
0.1780USD+4.154%(+0.0071)50,240,862
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 16, 2025 9:27:30 AM EDT
0.1785USD+4.447%(+0.0076)762,250
After-hours
May 16, 2025 4:53:30 PM EDT
0.1778USD-0.112%(-0.0002)82,122
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 4, 2022
08:00AM EST  Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences:   GlobeNewswire Inc
Dec 17, 2021
10:18AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021   Benzinga
06:24AM EST  HC Wainwright & Co. Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $26   Benzinga
Dec 3, 2021
10:17AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021   Benzinga
05:21AM EST  Baird Initiates Coverage On Vor Biopharma with Outperform Rating, Announces Price Target of $38   Benzinga
Dec 2, 2021
11:22AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2021   Benzinga
05:09AM EST  Oppenheimer Initiates Coverage On Vor Biopharma with Outperform Rating, Announces Price Target of $30   Benzinga
Nov 29, 2021
08:00AM EST  Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vors President and Chief Executive Officer, will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit.   GlobeNewswire Inc
Nov 19, 2021
04:01PM EST  Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vors President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Healthcare Conference.   GlobeNewswire Inc
Nov 10, 2021
05:45PM EST  Vor Biopharma Q3 EPS $(0.50) Up From $(61.23) YoY   Benzinga
Nov 9, 2021
08:30AM EST  Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell therapy platform at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place in Washington D.C., from November 10-14, 2021.   GlobeNewswire Inc
Nov 8, 2021
08:00AM EST  Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vors President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vors Chief Financial Officer, will be participating in two upcoming virtual investor conferences:   GlobeNewswire Inc
Oct 19, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021   Benzinga
07:26AM EDT  Vor To Present Data From Its Novel Cell And Genome Engineering Platform At ESGCT   Benzinga
07:05AM EDT  JMP Securities Initiates Coverage On Vor Biopharma with Market Outperform Rating, Announces Price Target of $40   Benzinga
07:00AM EDT  Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of data from its novel engineered hematopoietic stem cell (eHSC) platform at the ESGCT Annual Congress, taking place virtually October 19-22, 2021.   GlobeNewswire Inc
Oct 12, 2021
08:00AM EDT  Vor Strengthens Leadership Team with Addition of Dr. Veit   GlobeNewswire Inc
Sep 10, 2021
02:37AM EDT  Vor Biopharma (VOR), a clinical-stage cell and genome engineering company, announced that its VOR33 was granted Fast Track designation by the U.S. Food and Drug Administration. VOR33 is Vor's lead engineered hematopoietic stem cell or eHSC therapeutic candidate for the treatment of acute myeloid leukemia or AML.   RTTNews
Sep 9, 2021
08:02AM EDT  VOR33 Granted U.S. FDA Fast Track Designation For AML   Benzinga
08:00AM EDT  Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Companys lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).   GlobeNewswire Inc
Sep 2, 2021
08:00AM EDT  Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today announced that the Company will be participating in three upcoming virtual investor conferences:   GlobeNewswire Inc
Aug 9, 2021
04:40PM EDT  Vor Biopharma Q2 Net Loss $18.4M vs $8M In Same Qtr. Last Year   Benzinga
04:05PM EDT  -- On track to report initial VOR33 clinical data in the first half of 2022 -- Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignancies -- Initiated build-out of in-house clinical manufacturing facility   GlobeNewswire Inc
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 8, 2021
09:28AM EDT  Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia   Benzinga
08:02AM EDT  Vor Biopharma Announces Collaboration With Janssen To Develop Engineered Hematopoietic Stem Cell Transplants Combined With A Bi-Specific Antibody Therapy For Acute Myeloid Leukemia; Financial Details Not Disclosed   Benzinga
08:00AM EDT  Vor Biopharma Announces Collaboration with Janssen to Develop   GlobeNewswire Inc
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jun 17, 2021
08:00AM EDT  Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility   GlobeNewswire Inc
Jun 11, 2021
08:15AM EDT  Vor Biopharma Names Matthew Patterson As Chairman; Tania Philipp Promotes To Chief People Officer   RTTNews
08:00AM EDT  Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes   GlobeNewswire Inc
Jun 10, 2021
08:00AM EDT  Vor to Develop Multi-Targeted CAR-Ts with Abound Bio   GlobeNewswire Inc
May 25, 2021
04:10PM EDT  Vor Biopharma to Present at Jefferies and Goldman Sachs Investor   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
04:59PM EDT  Vor Q1 EPS $(0.67), Up From $(59.06) YoY   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
Apr 28, 2021
08:25AM EDT  Vor To Present On VOR33 Manufacturing Scale-Up And Off-Target Editing At ASGCT   Benzinga
08:00AM EDT  Vor Biopharma (Nasdaq: VOR) is pleased to announce that Vor scientists will give two presentations documenting the development, manufacturing, and validation of its engineered hematopoietic stem cell (eHSC) clinical candidate VOR33 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place virtually May 11-14, 2021.   GlobeNewswire Inc
Mar 25, 2021
04:36PM EDT  Vor Biopharma Reports FY20 Net Loss Of $43.3M Compared To $10.8M YoY   Benzinga
04:35PM EDT  IND accepted for VOR33, Vors lead eHSC product candidate for treatment of AML   GlobeNewswire Inc
10:17AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2021   Benzinga
08:25AM EDT  B. Riley FBR Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $60   Benzinga
Mar 5, 2021
03:00PM EST  Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Barclays Global Healthcare Conference, which will take place virtually on March 9-11, 2021.   GlobeNewswire Inc
Mar 3, 2021
12:21PM EST  Barclays Initiates Coverage On Vor Biopharma with Overweight Rating, Announces Price Target of $56   Benzinga
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2021   Benzinga
07:49AM EST  Evercore ISI Group Initiates Coverage On Vor Biopharma with Outperform Rating, Announces Price Target of $48   Benzinga
Mar 2, 2021
01:42PM EST  Stifel Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $58   Benzinga
01:41PM EST  Goldman Sachs Initiates Coverage On Vor Biopharma with Sell Rating, Announces Price Target of $19   Benzinga
Mar 1, 2021
03:45PM EST  Vor Biopharma Announces Participation at Cowen 41st Annual Health   GlobeNewswire Inc
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 13, 2021
12:54PM EST  The Past Week's Notable Insider Buys: Biotech IPOs, Curiositystream, Greenbrier And More   Benzinga
Feb 9, 2021
04:05PM EST  Vor Biopharma Closes Over $200M Initial Public Offering, Including   GlobeNewswire Inc
Feb 5, 2021
11:21AM EST  Vor Biopharma Corp Shares Open For Trade At $42.02; IPO Priced At $18/Share   Benzinga
10:40AM EST  Vor Biopharma Shares Will Open For Trade At 10:35 a.m. EST, Expected To Open After 10:45 a.m. EST; IPO Priced At $18/Share   Benzinga
06:38AM EST  Vor Biopharma Prices 9.8M IPO At $18/Share   Benzinga
06:34AM EST  Vor Biopharma Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC